Semaglutide shots for weight loss: what you actually need to know

You've heard about semaglutide shots and you want to know if they're the real thing

Fair question. The noise around these injections has been enormous, and not always accurate. Semaglutide, sold for weight management as Wegovy, is a genuine medicine with a solid evidence base and a full UK marketing authorisation. It is not a supplement, not a compounded preparation, and not a cosmetic treatment. The MHRA licenses it specifically for adults managing weight alongside reduced-calorie eating and increased activity.

What it does, mechanically: semaglutide binds to GLP-1 receptors in the brain and gut. The effect is a meaningful reduction in appetite and a slowing of gastric emptying, so meals feel filling sooner and that fullness lasts longer. The result, across the clinical trial programme, was consistent enough that NICE recommended it for NHS use under specific criteria. The NHS medicines page for semaglutide sets out the mechanism, common side effects and storage requirements clearly, worth a read before your first pen arrives.

One practical checking habit worth building: before you inject, hold the pen up to the light for a few seconds and look at the liquid. It should be clear and colourless. If it looks cloudy, discoloured or contains particles, do not use it, contact your prescriber and pharmacy. Takes ten seconds and matters more than most people realise.

The shots are administered once a week, on the same day each week if possible, into the abdomen, thigh or upper arm. The pen is pre-filled; there is no drawing up of liquid or measuring of doses. Injection technique matters, the full guide to taking Wegovy shots covers site rotation and what to do if you miss a day.

What the semaglutide shot trials actually showed, and what they didn't

The headline figure from STEP 1 is around 15% average weight reduction over 68 weeks at the 2.4 mg maintenance dose. That was a randomised controlled trial, published in the New England Journal of Medicine, involving adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. Participants also followed a reduced-calorie diet and increased their activity levels, the injection does not replace those habits, it makes them easier to sustain.

The trial evidence for Wegovy's weight-loss results is robust, but a few caveats matter. Average figures are averages, some participants lost considerably more, others less. Results depend on dose reached, how long treatment continues, and lifestyle factors alongside the medicine. Stopping the injections typically leads to gradual weight regain; this is a biological response, not a character flaw. It is also one reason why ongoing prescriber review before every repeat matters rather than just auto-renewing a supply.

A newer development worth knowing: the MHRA approved a 7.2 mg maintenance dose of semaglutide (initially as three 2.4 mg pens weekly, then via a dedicated single-dose 7.2 mg pen approved on 14 April 2026) for adults with a BMI of 30 or above. Trials reported approximately 20.7% average weight loss at 72 weeks at this higher dose, narrowing the gap with tirzepatide results. Whether that dose is appropriate for any individual is a clinical decision, not a self-selecting one. If you want to understand how rebellious semaglutide fits into the broader picture, or to compare the options side by side, the broader semaglutide overview page covers both the injection and the newly approved oral form.

Who the shots are licensed for, and why eligibility isn't just a BMI number

The UK licence for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as hypertension, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Those thresholds sit 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK clinical guidance.

BMI alone never settles the question. A prescriber reviews your full medical picture: current medicines, relevant conditions, contraindications, and whether anything in your history suggests a different approach would serve you better. History of medullary thyroid carcinoma or a condition called MEN2, for instance, means these injections are not appropriate. Semaglutide shots are also not recommended during pregnancy, breastfeeding, or when trying to conceive, and they are not licensed for anyone under 18. These are not small-print points; they are the reason clinical assessment is the compulsory first step, not an optional formality.

On the NHS, access to Wegovy runs through specialist weight management services under NICE's appraisal criteria, with waiting lists that are commonly long in most areas. Private weight-loss treatment through a regulated online pharmacy is an alternative for people who don't meet the NHS thresholds yet, or who would rather not wait. For questions about what the private route actually costs, the Wegovy pricing page sets out honest context, including what legitimate private prescriptions include beyond the medicine itself.

Side effects: what's common, what needs prompt attention

The side-effect profile of semaglutide shots is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, indigestion, reflux and burping are the most frequently reported. These are most noticeable after starting treatment or after a dose increase, and they often settle within a week or two as the body adjusts. Staying well hydrated and eating smaller, lower-fat meals in the early weeks helps most people through the adjustment.

More serious effects are less common but require prompt attention. Acute pancreatitis is a known risk with GLP-1 medicines, the MHRA issued a Drug Safety Update in January 2026 flagging it specifically. The symptom to act on is severe, persistent stomach pain that may travel to the back, with or without vomiting; if that happens, stop the injection and seek urgent medical help. Gallbladder problems, allergic reactions, and symptoms of significant dehydration from severe vomiting or diarrhoea also warrant medical contact rather than waiting to see how things go.

If you experience any side effect you're uncertain about, our aftercare team is available seven days a week. Suspected side effects can also be reported directly to the MHRA through the Yellow Card scheme, a straightforward online form that takes a few minutes and genuinely informs national safety monitoring. If you'd like to read more about how other people manage the early weeks, the general FAQs cover some of the most common practical questions. When you're ready to talk to a prescriber, starting a free consultation is the way to begin.